Whisone AnalystInvestor workspace
MAYBAKERHealthcareUpdated 3h ago

MAYBAKER

MAYBAKER (MAYBAKER) is listed on the Nigerian Exchange in the Healthcare sector, with exposure to Pharmaceutical Preparations. This page brings together the current share price, valuation, dividend context, business summary, and a practical 12-week outlook so you can assess the stock faster.

Sector

Healthcare

Market cap

₦67.9B

Dividend yield

1.0%

P/E ratio

15.30

Current price

₦39.35

Updated Updated 3h ago

Wait (12-week)

12-week outlook signal

Research score58/100

P/B

4.97

RSI

61.47

52W high

₦48.00

52W low

₦8.10

Valuation view

Looks relatively cheap vs peers

Income view

Low income profile

Momentum view

Momentum is balanced

Risk view

Lower volatility profile

Business trend

Latest operating data is available

Maybaker is a company in the pharmaceutical preparations industry that develops, manufactures, or distributes medicines and related health products. It makes money by selling those pharmaceutical products to hospitals, pharmacies, and other customers, earning revenue from product sales and distribution.

Investors usually follow MAYBAKER for its dividend profile, valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.

Why this stock stands out

What looks attractive right now.

It trades on a lower P/E than the current peer average in Healthcare.

Return on equity is healthy at roughly 32.5%, which suggests the business is using shareholder capital well.

Latest revenue

₦38.3B

Most recent reported period.

Latest net profit

₦4.44B

Most recent reported period.

ROE

32.5%

Return on equity

Debt / equity

0.42

Lower is usually safer.

P/B ratio

4.97

Useful for book value support.

Dividend yield

1.0%

Current income signal.

Explain the key numbers

P/E ratio

15.30

Price-to-earnings shows what investors pay for every ₦1 of profit. Lower can signal cheaper valuation, but only if profits are reliable.

Compare P/E with peers in the same sector to avoid false signals.

₦0.50

2026-05-20

Payment: 2026-06-04 · Qualification: 2026-05-19

₦0.40

2025-05-21

Payment: 2025-06-05 · Qualification: 2025-05-20

₦0.30

2024-05-22

Payment: 2024-06-06 · Qualification: 2024-05-21

₦0.30

2023-05-17

Payment: 2023-06-02 · Qualification: 2023-05-16

Watch the latest corporate action: Ex-dividend date.
Fundamentals were last updated 0 day(s) ago, so the next filing matters.
Monitor leverage discipline. Debt-to-equity is currently about 0.42x.

Ex-dividend date

2026-05-20

Estimated earnings date

2026-04-28

Estimated earnings date

2026-04-27

Price and session

Current price
₦39.35?
Open
₦39.35?
Previous close
₦38.05?
Day range
₦39.35 – ₦39.35?
52-week range
₦8.10 – ₦48.00?

Volume & liquidity

Today volume
1,319,857?
Average volume
1,375,497?
Volume vs average
0.96x?
Avg turnover/day
N/A
Tradeability
Moderate liquidity

Valuation

Market cap
₦67.9B?
P/E
15.30?
Forward P/E
N/A?
P/B
4.97?
Book value/share
7.91?

Momentum

Beta
0.62?
RSI
61.47?

Income & dividend

EPS
2.57?
Dividend yield
1.0%?
Dividend/share
₦0.50?
Ex-dividend date
2026-05-20?
Dividend records
5?

Latest financials

Revenue
₦38.3B?
Operating profit
₦6.25B?
Net income
₦4.44B
Operating cash flow
₦4.06B?
Capex
-₦1.16?

Event data

Estimated earnings date
2026-04-28

MAYBAKER

MAYBAKER

Price: ₦39.35

P/E: 15.30

Yield: 1.02%

AUSTINLAZ

AUSTINLAZ

Price: ₦3.73

P/E: N/A

Yield: N/A

FIDSON

FIDSON

Price: ₦99.50

P/E: 24.16

Yield: 1.51%

MCNICHOLS

MCNICHOLS

Price: ₦6.06

P/E: 19.54

Yield: 0.61%

Price updated

0d ago

Fundamentals updated

0d ago

Market cap

₦67.9B

Open

₦39.35

Previous close

₦38.05

Day range

₦39.35 – ₦39.35

52-week range

₦8.10 – ₦48.00

Volume

1,319,857

Average volume

1,375,497

Beta

0.62

RSI

61.47

Latest revenue

₦38.3B

Latest net profit

₦4.44B

Book value / share

7.91

TradeabilityModerate liquidity

Liquidity looks fair, but slippage can still happen if order size is too big.

Compare mode →AI Expert analysis →

Login to use AI Analyst.

Main risks

No single balance-sheet or earnings red flag stands out immediately, but this still needs peer and filing context.